HZHeba Mohamed Zaki

Heba Mohamed Zaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heba Mohamed Zaki has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    α-Klotho, hypoxia-inducible factor-2α, and oxidative stress in hemodialysis ‒ interactions with anemia, secondary hyperparathyroidism, and intradialytic hypotension

    by Heba Mohamed Zaki, Raghda E. Eldesouki, Shaymaa Abdelraheem Abdelhady, Mohamed Abdo, Marwa Mohamed Hosny

    Introduction and aim. End-stage renal disease (ESRD) is associated with oxidative stress (OS) and hormonal disturbances linked to anemia, secondary hyperparathyroidism (SHPT), and intradialytic hypotension (IDH). This study evaluated the expression of α-Klotho (α-KL) and hypoxia-inducible factor-2α (HIF-2α) together with OS markers in hemodialysis (HD) patients and explored their interrelationships and associations with anemia, SHPT, and IDH. Material and methods. Fifty HD patients and 50 healthy controls were evaluated for clinical and biochemical parameters, malondialdehyde (MDA), catalase (CAT) activity, and α-KL and HIF-2α expression. Correlation and network analyses were used to evaluate molecular interactions. Results. Anemia, SHPT, and IDH were identified in 72%, 44%, and 18% of HD patients, respectively. Compared with controls, HD patients demonstrated significantly higher MDA levels and lower α-KL and HIF-2α expression, and CAT activity (all p<0.001). MDA positively correlated with parathyroid hormone (PTH) (r=0.26, p<0.01) and IDH (r=0.37, p<0.001), but inversely with hemoglobin (Hb) (r=−0.24, p<0.02) and CAT activity (r=−0.36, p<0.001). Lower α-KL and HIF-2α expression levels, together with reduced CAT activity, correlated positively with Hb (r=0.27–0.71) and inversely with PTH (r=−0.27 to−0.62) and IDH (r=−0.40 to−0.92) (all p<0.01). Positive intercorrelations were additionally found among α-KL, HIF-2α, and CAT (r=0.21–0.38, all p<0.05). Conclusion. Reduced α-KL and HIF-2α expression together with altered OS markers were associated with anemia, SHPT, and IDH in HD patients. The close interrelationships observed among α-KL, HIF-2α, and OS markers may reflect an integrated molecular pattern linked to dialysis-related complications. Additional prospective studies are warranted to further elucidate these relationships.

  • Open Access

    Adherence to hemodialysis and medical regimens among patients with end-stage renal disease during COVID-19 pandemic: a cross-sectional study

    by Basma Osman Sultan, Ahmed Mahmoud Fouad, Heba M. Zaki

    Background: Adherence of patients with End-Stage Renal Disease (ESRD) to Hemodialysis (HD), prescribed medications, diet and fluid restrictions is essential to get the desirable outcome and prevent complications. During COVID-19 pandemic, ESRD patients became more concerned with attending the HD sessions and following the protective measures because of the potential for increased susceptibility to COVID-19. The aim of this study was to evaluate the impact of the pandemic on patients' adherence to HD and medical regimens.Methods: Two hundred five ESRD patients on HD were interviewed with the ESRD Adherence Questionnaire (ESRD-AQ) and the Fear-of-COVID-19 Scale (FCV-19S). Clinical and laboratory correlates of adherence were retrieved from patients' records.Results: Self-reported adherence to HD showed that 19.5% were not adherent to HD during the pandemic compared to 11.7% before the pandemic (p < 0.001), with a significant agreement with the actual attendance of HD sessions (Kappa = 0.733,p < 0.001). Twenty-five patients (12.2%) had a history of COVID-19. The FCV-19S had a mean score of 18.8 and showed significant positive correlations with the pre-dialysis phosphorus and potassium. Multivariate analysis showed that the main predictors of non-adherence were the history of COVID-19, understanding and perception scores, and the Fear-of-COVID score.Conclusions: The COVID-19 pandemic adversely affected the adherence of ESRD patients to HD and medical regimen. Strategies to mitigate patients' fears of COVID-19 and improve their understanding and perceptions of adherence to HD and medical regimen should be adopted in HD centers during the pandemic.


  • Silent neurological lesions detected by magnetic resonance imaging: Relationship to hyperparathyroidism among end‐stage renal disease young patients on haemodialysis

    by Heba M. Zaki, Hamdy A. Sliem, Heba R. Ibrahim, Imane A. Yassine

    Background End-stage renal disease (ESRD) patients on haemodialysis (HD) suffer from several peripheral and central neurological complications. They are at high risk for developing silent neurological lesions (SNL) that may be detected accidentally by magnetic resonance imaging (MRI). Many factors are implicated in the development of neurological deficits in ESRD patients on HD. Aim of the Work Evaluation of SNL in young ESRD patients by using MRI and assessing its correlation with hyperparathyroidism. Methods The study involved 48 young ESRD patients (mean age of 19.6 ± 6 years) with HD and do not have any apparent abnormalities in the neurological examination. Laboratory investigations and conventional brain MRI were done on all. Results 79.2% have SBI and 45.8% have white matter lesions. Regression analysis revealed that calcium level and duration of dialysis were independent predictor factors for the presence of silent brain MRI lesions (P = .034 & 0.045 respectively). ROC curve showed that parathyroid hormone (PTH) level >585 pg/mL, duration of dialysis >2 years, and calcium level >7.5 mg/dL predicted the presence of SNL. Conclusion The duration of HD and hyperparathyroidism (HPT) were independent predictors for the presence of SNL. MRI brain is considered as a mandatory affordable tool for HD patients >2 years and has HPT for early detection of SNL to help early intervention and avoid neurological complications and disabilities.


  • Urinary Monocyte Chemoattractant Protein -1 as A Diagnostic Marker of Lupus Nephritis

    by Gamal Tawfik, Eman Ghareeb, Waleed O Abd El-Waheed, Mohammed M Keshawy, Heba M Zaki


  • Open Access

    Erythropoietin hyporesponsiveness among egyptian hemodialysis patients

    by Salah, Alaa, Mohamed, Heba M. Zaki, Mohamed Msc, Salah Eldin Khedr, Alaa E. Saad

  • Open Access

    Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: A case-control study

    by Hamdy Sliem, Gamal Tawfik, Fadia Moustafa, Heba Zaki

    Introduction: Secondary hyperparathyroidism (SHPT) is an insidious disease that develops early in the course of chronic kidney disease (CKD) and increases in severity as the glomerular filtration rate deteriorates. Recent studies have identified fibroblast growth factor-23 (FGF23) as a new protein with phosphaturic activity. It is mainly secreted by osteoblasts and is now considered the most important factor for regulation of phosphorus homeostasis. It is not yet proven if there is any direct relation between parathyroid hormone (PTH) and FGF23. The present study aims to evaluate the relation between serum FGF23, phosphorus, and PTH in end-stage renal disease in patients with SHPT on regular hemodialysis. Materials and Methods: Forty-six consecutive CKD adult patients (case group) and 20 healthy adults (control group) were included in the study. All patients had SHPT and were on regular hemodialysis. Both groups were subjected to full medical history, clinical examination and biochemical studies. Serum phosphorus, calcium, ferritin, hemoglobin level, blood urea, creatinine, PTH, and FGF23 were analyzed. Results: Levels of FGF23 were significantly higher in the case group in comparison with those in the control group, viz., 4-fold, and positively correlated with PTH. Phosphorus levels in the case group were significantly high in spite of the increasing levels of FGF23. Both PTH and FGF23 were positively correlated with phosphorus and negatively with hemoglobin levels. Conclusion: SHPT and FGF23 may have a partial role in the development of anemia in patients with CKD. FGF23 could be a central factor in the pathogenesis of SHPT. Its role in controlling hyperphosphatemia in CKD is vague.